Associated Genetic Biomarkers
BCL6 Amplification is present in 0.40% of AACR GENIE cases, with squamous cell lung carcinoma, high grade ovarian serous adenocarcinoma, anal squamous cell carcinoma, breast invasive ductal carcinoma, and oral cavity squamous cell carcinoma having the greatest prevalence .
BCL6 Amplification serves as an inclusion eligibility criterion in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains BCL6 Amplification as an inclusion criterion, 1 is phase 2 (0 open).
Significance of BCL6 Amplification in Diseases
Mature B-Cell Lymphoma/Leukemia +
BCL6 Amplification is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCL6 Amplification and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.